FDA approves Amgen’s Repatha for heart attack and stroke prevention
Check out Repatha FDA approval news where we will tell you about the approval of the Amgen cholesterol drug for the prevention of heart attack and stroke.
In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart attacks, strokes, and coronary revascularizations in adults with heart disease. This marks the first approval of a PCSK9 inhibitor for these specific conditions, highlighting a major step forward in the […]